Prognostic role of KL‐6 in SSc‐ILD patients with pleuroparenchymal fibroelastosis
- 23 March 2021
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 51 (8) , e13543
Abstract
Background: Krebs von den Lungen‐6 (KL‐6) is a high‐molecular‐weight (200kDa) glycoprotein proposed as a diagnostic biomarker for differentiating interstitial lung disease (ILD). Systemic sclerosis (SSc) is a rare immune‐mediated disorder, and ILD is the leading cause of morbidity and mortality. Pleuroparenchymal fibroelastosis (PPFE) has been described to have a poor prognosis in SSc‐ILD patients. This study undertook to compare serial changes in KL‐6 in SSc‐ILD patients with and without PPFE, to verify its prognostic value as a disease biomarker.Materials and Methods: Twenty‐five SSc‐ILD patients (median IQR, 62 (56‐58); 20% males) were retrospectively enrolled. 12 SSc‐ILD patients (48%) had also a radiological diagnosis of PPFE. Serum KL‐6 concentrations were measured by KL‐6 reagent assay (Fujirebio Europe, Ghent, Belgium).Results: Serum KL‐6 measurements were increased in SSc‐ILD patients with and without PPFE compared with healthy controls (P < .0001). Comparative analysis of the rate of variation of KL‐6 over the 6 years of follow‐up was performed by serial two‐yearly KL‐6 measurements: Δ1(t1‐t0), Δ2(t2‐t1) and Δ3(t3‐t2). In SSc‐ILD patients with PPFE pattern, Δ3 was significantly different than those without PPFE pattern (P = .0020). Serum KL‐6 levels were significantly different (P = .0455) either at Δ2 and Δ3 in the PPFE group. In SSc‐ILD patients with PPFE, at t3 serum KL‐6 concentrations were inversely correlated with FEV1 (r = −.76; P = .037) and FVC percentages (r = −.79; P = .028).Conclusion: These results suggest that serial measurements of KL‐6 in the follow‐up of these patients may help to monitor disease progression. In real life, in SSc‐ILD patients PPFE should be always evaluated at CT and when present should suggest a tight follow‐up to monitor its evolution.Keywords
This publication has 42 references indexed in Scilit:
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013
- Clinical Features and Outcomes in Combined Pulmonary Fibrosis and Emphysema in Idiopathic Pulmonary FibrosisChest, 2013
- Utility of spiral CAT scan in the follow-up of patients with pulmonary Langerhans cell histiocytosisEuropean Journal of Radiology, 2012
- Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypesEuropean Respiratory Journal, 2012
- Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement: Table 1—European Respiratory Journal, 2009
- Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with SclerodermaThe Journal of Rheumatology, 2009
- How much do GOLD stages reflect CT abnormalities in COPD patients?La radiologia medica, 2008
- Interstitial Lung Disease in Systemic SclerosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Pulmonary Disease Assessment in Cystic Fibrosis: Comparison of CT Scoring Systems and Value of Bronchial and Arterial Dimension MeasurementsRadiology, 2004
- Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2002